ASRM 2019 — Preimplantation genetic testing does not harm embryos


  • Daniel M. Keller, Ph.D
  • Conference Reports
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Preimplantation genetic testing for aneuploidy (PGT-A) is safe for the embryo and does not discard embryos that may successfully implant and develop normally.

Why this matters

  • There has been concern that trophectoderm biopsy for PGT-A may harm embryos and may cause discard of embryos with significant reproductive potential. The study shows that neither concern has merit.

Study design  

  • Prospective, blinded, nonselection study.
  • Comparison of sustained implantation rate (SIR) of study group vs a control group without biopsy/PGT-A.
  • Assessment of PGT-A to correctly predict clinical outcomes (performed only after clinical outcome was known).
  • All participants (first in vitro fertilization cycle) underwent intracytoplasmic sperm injection, culture to blastocyst stage, biopsy, and freezing, with single embryo transfer (SET) in the next cycle.
  • Support: IVI America and the Foundation for Embryonic Competence.

Key results

  • SET n=440 for study group age-matched to 957 controls.
  • SIR: study group 49.2% vs controls 52.2% (OR, 0.85; 95% CI, 0.65-1.1; P=.33).
  • Predictive value of PGT-A for delivering: euploid, 64.9%; aneuploid, 0% (95% CI, 0%-2.4%).

Limitations

  • Study not powered to evaluate mosaic, segmental aneuploid, or mosaic segmental aneuploid diagnoses.
  • Results apply only to this assay for ploidy (Foundation for Embryonic Competence NexCCS).